Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can adding laser to foam therapy clear leg veins better?

NCT ID NCT07793630

Symptom relief Sponsor: University of Sao Paulo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This trial tests whether combining foam sclerotherapy with a transdermal laser clears spider and reticular leg veins more effectively than foam alone. Researchers will enroll 70 women with these veins on both legs, treating one leg with the combination and the other with foam only. They will measure vein clearance, pigmentation, pain, and satisfaction over 180 days to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Polidocanol foam sclerotherapy, with or without transdermal laser
What this could lead to
If the combined approach works better, it could offer a more effective, single-session treatment for spider and reticular leg veins, improving appearance and patient satisfaction.
What could go wrong
This is a small, early-stage trial in a specific group of women, so results may not apply to everyone. Risks include temporary bruising, pigmentation changes, or the need for additional drainage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 18 to 60 years. * Fitzpatrick skin phototype I, II, or III. * CEAP clinical class C1. * Bilateral relatively symmetrical presence of telangiectasias and reticular veins on the lateral thigh. * Presence of telangiectasias and reticular veins measuring 0.1 to 3 mm in diameter. * Body mass index (BMI) ≤ 30 kg/m² * Willingness to participate in the complete study follow-up and provision of written informed consent. Exclusion Criteria: * Saphenous or perforator venous reflux. * Varicose veins greater than 3 mm in diameter (CEAP C2-C6). * Fitzpatrick skin phototype IV, V, or VI. * Recent venous thrombosis or known thrombophilia. * Use of anticoagulant therapy. * Pregnancy or breastfeeding. * Known allergy to polidocanol. * Peripheral arterial disease with ankle-brachial index (ABI) \< 0.8. * Diabetes mellitus. * Local dermatitis in the treatment area. * Previous venous treatment within the last 6 months. * Failure to attend the treatment session or scheduled follow-up visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic venous disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic venous insufficiency Hyperpigmentation livedo reticularis telangiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic venous disease Reticular veins Telangiectasias

Contacts and locations

Locations

  • Clínica Civil - FAEPA USP

    Ribeirão Preto, São Paulo, 14040-900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.